Impact of an electronic antibiotic advice and approval system on antibiotic prescribing in an Australian teaching hospital

Medical Journal of Australia

Volumn 180, Issue 9, 2004, Pages 455-458

  Grayson, M Lindsay ^a,b,c   Melvani, Sharmila ^a   Kirsa, Sue W ^a   Cheung, Stephen ^a   Korman, Anthony M ^d   Garrett, M Kent ^a   Thomson, William A ^e  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

^e Victorian Drug Usage Advisory Committee   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; FAMCICLOVIR; MEROPENEM; NORFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; ROXITHROMYCIN; TIMENTIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; AUSTRALIA; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER PROGRAM; COMPUTER SYSTEM; CONSULTATION; DRUG APPROVAL; DRUG INDICATION; DRUG USE; ELECTRONICS; EVIDENCE BASED MEDICINE; HOSPITAL MANAGEMENT; HUMAN; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OUTCOMES RESEARCH; PHARMACIST; PRESCRIPTION; STAFF TRAINING; STAPHYLOCOCCUS INFECTION; TEACHING HOSPITAL; TELEPHONE;

EID: 2442468034     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2004.tb06022.x     Document Type: Article

References (11)

1. McManus P, Hammond ML, Whicker SD, et al. Antibiotic use in the Australian community, 1990-1995, Med J Aust 1997; 167: 124-127.
2. World Health Organization. WHO global strategy for containment of antimicrobial resistance. Geneva: WHO, 2001.
3. World Health Organization report on infectious diseases 2000: overcoming antimicrobial resistance. Chapter 3: factors contributing to resistance. WHO, 2000. Available at: www.who.int/infectious-disease-report/2000 (accessed Mar 2004),
4. Robertson MB, Dartnell JG, Korman TM, on behalf of the Victorian Drug Usage Evaluation Group, Vancomycin and teicoplanin use in Victorian hospitals. Med J Aust 1999; 171: 127-131.
5. Robertson MB, Korman TM, Dartnell JG, et al, on behalf of the Victorian Drug Usage Evaluation Group. Ceftriaxone and cefotaxime use in Victorian hospitals. Med J Aust 2002; 176: 524-529.
6. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
7. Johnson PDR, Irving LB, Turnidge JD, Community-acquired pneumonia. Med J Aust 2002; 176: 341-347.
8. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
9. World Health Organization. ATC index with DDDs. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology, 2003. Available at: www.whocc.no/ atcddd (accessed Mar 2004).
10. Therapeutic guidelines: antibiotic. 12th ed. Melbourne: Therapeutic Guidelines Limited, 2003.
11. Richards MJ, Robertson MB, Dartnell JG, et al. Impact of a web-based antimicrobial approval system on broad-spectrum cephalosporin use at a teaching hospital. Med J Aust 2003; 178: 386-390.